# **Health Products Regulatory Authority**

# **Summary of Product Characteristics**

#### **1 NAME OF THE MEDICINAL PRODUCT**

Flixotide Evohaler 125 micrograms per metered dose pressurised inhalation suspension

## **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each metered dose contains 125 micrograms of fluticasone propionate.

For the full list of excipients, see section 6.1.

#### **3 PHARMACEUTICAL FORM**

Pressurised inhalation, suspension (Pressurised Inhalation).

Product imported from Greece, Norway and the Netherlands:

Pressurised inhalation suspension supplied in an aluminium can with metering valve and actuator.

#### **4 CLINICAL PARTICULARS**

As per PA1077/044/014

## **5 PHARMACOLOGICAL PROPERTIES**

As per PA1077/044/014

#### **6 PHARMACEUTICAL PARTICULARS**

# 6.1 List of excipients

Norflurane (Hydrofluroalkane (HFA 134a))

## 6.2 Incompatibilities

Not applicable.

#### 6.3 Shelf life

The shelf-life expiry date of this product shall be the date shown on the container and outer package of the product on the market in the country of origin.

## 6.4 Special precautions for storage

Do not store above 30°C.

Do not refrigerate or freeze.

Store in the original package.

Protect from frost and direct sunlight.

The canister contains a pressurised liquid. Do not expose to temperatures higher than 50°C. Do not pierce, burn or break the canister, even when apparently empty.

Replace the mouthpiece cover firmly and snap it into position.

13 January 2022 CRN00CPZ2 Page 1 of 2

## **Health Products Regulatory Authority**

As with most inhaled medications in pressurised canisters, the therapeutic effect of this medication may decrease when the canister is cold.

## 6.5 Nature and contents of container

The suspension is contained in an aluminium pressurised can with a metering valve. The can is fitted into a plastic actuator incorporating an atomising orifice and fitted with a dustcap. Pack size: 120 metered doses per inhaler.

# 6.6 Special precautions for disposal and other handling

Patients should be carefully instructed in the correct use of the inhaler.

Shake before use.

## 7 PARALLEL PRODUCT AUTHORISATION HOLDER

PCO Manufacturing Ltd.
Unit 10, Ashbourne Business Park
Rath
Ashbourne
Co. Meath
Ireland

#### **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA0465/073/001

# 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 07 July 2001

Date of last renewal: 07 July 2006

Last updated: April 2011 Last updated: May 2014

June 2015 April 2021

# 10 DATE OF REVISION OF THE TEXT

January 2022

13 January 2022 CRN00CPZ2 Page 2 of 2